Manuel Seneriz, MD
Urology · Inverness, FLNPI 1942271481
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $9,500 of the $10,364 with a category attached, or 91.7%. Laser Specialty Medical, LLC accounts for 91.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $3,539 and has fallen 90.3% since, to $342 in 2025.
Across 25 payments — averaging $414.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Laser Specialty Medical, LLC$10K
- Astellas Pharma US Inc$253
- Boston Scientific$155
- Ferring Pharmaceuticals Inc.$120
- Axonics, Inc.$63
- Procept Biorobotics Corporation$47
- plus $226 from 10 others
What the payments were for
- Food & beverage$6646%
- Education$2002%
- Ownership interest$9,50092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Laser Specialty Medical, LLC | 3 | $9,500 |
| Astellas Pharma US Inc | 5 | $253 |
| Boston Scientific | 2 | $155 |
| Ferring Pharmaceuticals Inc. | 1 | $120 |
| Axonics, Inc. | 1 | $63 |
| Procept Biorobotics Corporation | 1 | $47 |
| Pfizer | 3 | $40 |
| Teleflex LLC | 1 | $36 |
| Olympus America Inc. | 1 | $31 |
| Neotract Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,364 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 89 | $78,744 |
| MyrbetriqMirabegron | 52 | $62,741 |
| Tamsulosin Hcl | 1,515 | $26,758 |
| Finasteride | 771 | $11,011 |
| PremarinEstrogens, Conjugated | 17 | $8,752 |
| Bicalutamide | 68 | $6,150 |
| Testosterone | 26 | $4,488 |
| Silodosin | 44 | $3,997 |
| Doxazosin Mesylate | 204 | $3,571 |
| Methenamine Hippurate | 55 | $3,527 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 102 | $2,241 |
| Tadalafil | 33 | $2,145 |
| Oxybutynin Chloride ErOxybutynin Chloride | 52 | $2,080 |
| Oxybutynin Chloride | 119 | $1,846 |
| Testosterone Cypionate | 26 | $1,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $253 | $62,74152 claims |
| PfizerPremarin | $40 | $8,75217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Inverness
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.